For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Mirati Therapeutics, Inc.

USPTO Granted Patents = 38

EPO Patents = 9

Trademarks = 19

Forward Citations = 86

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Matthew Arnold Marx (26 out of 26 patents)

James Gail Christensen (20 out of 21 patents)

Aaron Craig Burns (14 out of 18 patents)

4. John Michael Ketcham (14 out of 22 patents)

5. Christopher Ronald Smith (12 out of 27 patents)

6. John David Lawson (10 out of 24 patents)

7. Thomas P Bobinski (8 out of 10 patents)

8. John Peter Fischer (8 out of 26 patents)

9. Jay Bradford Fell (7 out of 23 patents)

10. James F Blake (7 out of 112 patents)

11. Mark Joseph Chicarelli (7 out of 44 patents)

12. Pavel Savechenkov (7 out of 7 patents)

13. Tony P Tang (7 out of 40 patents)

14. Matthew Randolph Lee (7 out of 10 patents)

15. Xiaolun Wang (7 out of 22 patents)

38 patents: Sort by Forward Citations

1. 12485122 - Combination of palbociclib and adagrasib for lung cancer (2025-12-02),

2. 12466838 - Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof (2025-11-11),

3. 12421253 - Tetrahydropyridopyrimidine pan-KRas inhibitors (2025-09-23),

4. 12421228 - Naphthyridine derivatives as PRC2 inhibitors (2025-09-23),

5. 12398154 - Azaquinazoline pan-KRas inhibitors (2025-08-26),

6. 12383503 - Adagrasib solid pharmaceutical compositions (2025-08-12),

7. 12377101 - Combination therapies (2025-08-05),

8. 12371435 - Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors (2025-07-29),

9. 12336995 - Combination therapies (2025-06-24),

10. 12304915 - SOS1 inhibitors (2025-05-20),

11. 12286431 - Crystalline forms of a KRas G12C inhibitor (2025-04-29),

12. 12281113 - Crystalline forms of a KRas G12C inhibitor (2025-04-21),

13. 12280055 - Combination therapies (2025-04-21),

14. 12252493 - Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer (2025-03-18),

15. 12208099 - Combination therapies (2025-01-28),

Mirati Therapeutics is a clinical-stage targeted oncology company focused on developing a pipeline of precision oncology products to treat patients with various types of cancer. Their research and development efforts are centered on small molecule inhibitors designed to target specific genetic and epigenetic drivers of cancer cell growth. With a commitment to bringing innovative therapies to patients in need, Mirati Therapeutics aims to advance transformational treatments to improve outcomes in cancer care.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

38 Patents

#152 in San Diego, CA

#2,068 in California

#8,725 in US

#17,311 in the World

San Diego, CA, United States of America

Mirati Therapeutics, Inc.

Forward Citations = 86

62 inventors:

Matthew Arnold Marx (26 out of 26 patents)

James Gail Christensen (20 out of 21 patents)

Aaron Craig Burns (14 out of 18 patents)

4. John Michael Ketcham (14 out of 22 patents)

5. Christopher Ronald Smith (12 out of 27 patents)

Please report any incorrect information to support@idiyas.com

Loading…